Supercharge Your Innovation With Domain-Expert AI Agents!

Medicine prepared from sodium butyrate and used for preventing, controlling and treating eye diseases and application thereof

A technology of sodium butyrate and medicine, which is applied to the medicine for treating eye diseases, the application in the preparation of the above medicine, prevention and control, to achieve the effect of inhibiting the leakage of blood vessels, wide sources and low price

Inactive Publication Date: 2021-05-25
汕头大学·香港中文大学联合汕头国际眼科中心
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the application of sodium butyrate in the treatment of ocular neovascular diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine prepared from sodium butyrate and used for preventing, controlling and treating eye diseases and application thereof
  • Medicine prepared from sodium butyrate and used for preventing, controlling and treating eye diseases and application thereof
  • Medicine prepared from sodium butyrate and used for preventing, controlling and treating eye diseases and application thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0050] [Experimental example 1 Sodium butyrate inhibits tube formation of HUVEC cells cultured in vitro]:

[0051] 1. Materials and reagents: sodium butyrate solution (prepared in PBS, pH 7.4), human umbilical vein blood endothelial cells (HUVEC), Matrigel matrigel, EBM-2 endothelial cell basal culture medium, complete culture medium.

[0052] 2. Experimental equipment: inverted phase contrast microscope, cell incubator, counting plate, 48-well plate, EP tube, pipette tip.

[0053] 3. Experimental steps:

[0054] 1. Preparation before the experiment: HUVEC cells were cultured in complete culture medium, and the cells were in good condition. The cells were subcultured to the logarithmic growth phase 24 hours before the experiment; , stored at -80°C), thaw Matrigel matrigel on ice 1 hour before the experiment, and pre-cool pipette tips, EP tubes, and 48-well plates on ice;

[0055] 2. Spreading gel: Dilute EBM-2 and Matrigel 1:1, mix well, disperse and spread on 48-well plat...

experiment example 2

[0060] [Experimental Example 2 Sodium butyrate inhibits the proliferation of HUVEC cells cultured in vitro]:

[0061] 1. Materials and reagents: sodium butyrate solution (prepared in PBS, pH 7.4), human umbilical vein blood endothelial cells (HUVEC), ordinary cell culture medium (DMEM), endothelial cell basal culture medium EBM-2 (without growth factors ), fetal bovine serum (FBS), antibiotic P / S, MTT reagent.

[0062] 2. Experimental equipment: ultra-clean bench, cell incubator, counting plate, inverted phase contrast microscope, cell incubator, NanoDrop spectrophotometer.

[0063] 3. Experimental steps:

[0064] 1. Species of cells: HUVEC were cultured to the logarithmic growth phase with ordinary high-glucose medium, the cells were digested, centrifuged and counted, 9x10 3 The density of cells / well was seeded in a 96-well plate and placed at 37°C / 5%CO 2 overnight in an incubator;

[0065] 2. Dosing: Dilute NaBu with ordinary complete culture medium to concentrations o...

experiment example 3

[0069] [Experimental example 3 Sodium butyrate inhibits choroidal budding experiment]:

[0070] 1. Materials and reagents: sodium butyrate solution (prepared in PBS, PH=7.4), C57 / BL6J healthy mice (8th day after birth, P8), endothelial cell growth medium EGM-2 (EBM-2 + growth factor ), Matrigel, pyruvate-PBS buffer (PBS+2X antibiotic P / S+1X pyruvate).

[0071] 2. Experimental equipment: Stereo microscope, ultra-clean table, cell culture box, 24-well plate, surgical instruments for ophthalmic anatomy, and inverted microscope.

[0072] 3. The first part of the experiment: detecting the effect of different concentrations of NaBu treatment on choroidal budding

[0073] Experimental steps:

[0074] 1. Isolation of tissues: C57 / BL6J mice on day 8 (P8) after birth were taken out and sacrificed by dislocation of the neck. Immediately, the eyeballs were taken out, rinsed twice in the prepared pyruvate-PBS buffer, cut the cornea, and removed the lens, Vitreous body, retina, separate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine for treating eye diseases, in particular to a medicine prepared from sodium butyrate as an active ingredient and the application of the sodium butyrate in preparation of the medicine. The sodium butyrate in the medicine inhibits pathological hyperplasia of eye tissue blood vessels through dosage forms of whole-body application, coating application, injection application and eyeball implant application, and the treatment effect of the eye diseases is improved. The eye diseases caused by blood vessel leakage and scar formation due to pathological hyperplasia of eye tissue blood vessels are prevented, controlled and treated.

Description

technical field [0001] The invention relates to a medicine for treating eye diseases, in particular to medicines for the prevention, control and treatment of eye diseases prepared with sodium butyrate as an active ingredient, and the application thereof in the preparation of the above medicines. Background technique [0002] The formation of neovascularization is regulated by many angiogenesis-related factors, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor-B (PDGF-B), placental growth factor (PIGF), pigment epithelium-derived factor (PEDF), and vascular inhibitory factors. Synergistic regulation of element (AS) and so on. Among them, VEGF plays a major role in affecting symptoms or diseases caused by neovascularization. [0003] The mechanism of such symptoms or diseases is due to the increased concentration of VEGF, which in turn produces unhealthy new blood vessels. These new blood vessels are not only not conducive to the repair of dama...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/19A61P27/02A61P9/10A61P27/06
CPCA61K31/19A61P27/02A61P9/10A61P27/06
Inventor 陈浩宇肖小强陈敏
Owner 汕头大学·香港中文大学联合汕头国际眼科中心
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com